Trivium Point Advisory LLC Takes $4.15 Million Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Trivium Point Advisory initiated a $4.15 million position in Thermo Fisher Scientific during the second quarter by purchasing 8,277 shares. Institutional investors collectively own 89.23% of the company.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $619.41; recent targets range from $570 to $650.
• Thermo Fisher exceeded quarterly expectations, reporting $6.03 in EPS and $11.99 billion in revenue, with revenue up 10.5% year over year. The company also declared a quarterly dividend of $0.47 per share.

Trivium Point Advisory LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 8,277 shares of the medical research company's stock, valued at approximately $4,150,000.

A number of other institutional investors have also recently made changes to their positions in TMO. High Note Wealth LLC increased its stake in shares of Thermo Fisher Scientific by 170.6% in the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after buying an additional 29 shares during the period. Swiss RE Ltd. bought a new stake in Thermo Fisher Scientific in the 4th quarter worth $28,000. Legacy Wealth Managment LLC ID increased its position in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after acquiring an additional 22 shares during the period. Birchwood Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Finally, Core Wealth Advisors LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, VP Lisa P. Britt sold 5,850 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the completion of the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at approximately $8,574,720. This trade represents a 28.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last quarter. 0.33% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TMO shares. Jefferies Financial Group reiterated a "buy" rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Royal Bank Of Canada raised their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a research report on Friday, July 24th. Evercore set a $570.00 target price on Thermo Fisher Scientific in a report on Monday, July 6th. Barclays increased their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an "overweight" rating in a research note on Friday, July 24th. Finally, Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $619.41.

Thermo Fisher Scientific Trading Down 0.3%

Shares of NYSE:TMO opened at $586.62 on Tuesday. The stock's 50-day simple moving average is $531.72 and its two-hundred day simple moving average is $508.48. The stock has a market capitalization of $216.90 billion, a price-to-earnings ratio of 31.56, a PEG ratio of 2.39 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source